Advisors Capital Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,112
| Closed | -$505K | – | 530 |
|
|
2024
Q3 | $505K | Buy |
5,112
+37
| +0.7% | +$3.66K | 0.01% | 367 |
|
|
2024
Q2 | $471K | Sell |
5,075
-121
| -2% | -$11.2K | 0.01% | 367 |
|
|
2024
Q1 | $493K | Buy |
5,196
+77
| +2% | +$7.31K | 0.01% | 361 |
|
|
2023
Q4 | $457K | Buy |
5,119
+556
| +12% | +$49.6K | 0.01% | 356 |
|
|
2023
Q3 | $333K | Buy |
4,563
+248
| +6% | +$18.1K | 0.01% | 345 |
|
|
2023
Q2 | $359K | Sell |
4,315
-493
| -10% | -$41K | 0.01% | 352 |
|
|
2023
Q1 | $366K | Buy |
4,808
+427
| +10% | +$32.5K | 0.01% | 337 |
|
|
2022
Q4 | $364K | Buy |
4,381
+549
| +14% | +$45.6K | 0.01% | 348 |
|
|
2022
Q3 | $322K | Sell |
3,832
-957
| -20% | -$80.4K | 0.01% | 385 |
|
|
2022
Q2 | $356K | Buy |
4,789
+1,712
| +56% | +$127K | 0.01% | 338 |
|
|
2022
Q1 | $277K | Buy |
3,077
+732
| +31% | +$65.9K | 0.01% | 379 |
|
|
2021
Q4 | $263K | Buy |
2,345
+395
| +20% | +$44.3K | 0.01% | 382 |
|
|
2021
Q3 | $245K | Buy |
1,950
+17
| +0.9% | +$2.14K | 0.01% | 378 |
|
|
2021
Q2 | $262K | Sell |
1,933
-140
| -7% | -$19K | 0.01% | 345 |
|
|
2021
Q1 | $281K | Buy |
2,073
+108
| +5% | +$14.6K | 0.01% | 323 |
|
|
2020
Q4 | $276K | Sell |
1,965
-203
| -9% | -$28.5K | 0.01% | 306 |
|
|
2020
Q3 | $242K | Buy |
2,168
+37
| +2% | +$4.13K | 0.01% | 281 |
|
|
2020
Q2 | $239K | Buy |
+2,131
| New | +$239K | 0.01% | 268 |
|